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In pediatric oncology, there is no evidence-based definition of the temperature limit defining fever 
(TLDF), which itself is essential for the definition of fever in chemotherapy-induced severe neutropenia 
(FN). Lowering the TLDF can increase the number of FN episodes diagnosed. This prospective, single 
center observational study collected data on all temperature measurements, complete blood counts 
(CBCs), and measures of diagnostics and therapy performed at and after FN diagnosis in pediatric 
oncology patients using a high standard TLDF (39 °C ear temperature). In 45 FN episodes in 20 patients, 
3391 temperature measurements and 318 CBCs, plus information on antibiotics, anti-fungal therapy, 
antipyretics, blood cultures taken and on discharge were collected. These data can mainly be used to 
study the influence of virtually lowering the TLDF on diagnostic measures, treatment and length of 
hospitalization in pediatric FN, which in turn are directly related to costs of FN therapy, and quality of 
life. This approach can be expanded to include as well different definitions of neutropenia.
Background & Summary
In children with cancer, fever in chemotherapy-induced neutropenia (FN) is the most frequent potentially lethal 
complication and the leading cause of emergency hospitalization1. Empirical therapy with broad-spectrum anti-
biotics, usually given intravenously in an in-house setting, are routine measures. They have led to a reduction of 
the FN associated mortality below 1% in developed countries2. However, there is no international consensus on 
temperature-limits defining fever (TLDF) for children with chemotherapy-induced severe neutropenia, despite 
its relevance for the clinical diagnosis and management of FN1,3,4. Published data on clinically used TLDF shows a 
wide range from 37.5 °C to 39.0 °C5–7. Through this inconsistency, the diagnosis of FN is made at varying temper-
atures. This reflects the fact that there is no internationally accepted evidence-based TLDF definition in pediatric 
fever in neutropenia1.
The TLDF applied determines not only the diagnosis of FN itself with initiation of therapy, but also the clinical 
measures of diagnostics and treatment during the whole hospitalization for FN. These measures include the num-
ber of blood cultures taken, the time-point of escalating empirical antibiotic therapy and the addition of empirical 
antifungal treatment in case of persisting fever1. Moreover, it influences the time point of hospital discharge and 
thus the length of hospitalization. These measures have a direct impact on the individual patient, including qual-
ity of life, and also on resource utilization and treatment costs8.
The here presented data9 has been collected during a prospective single-center study (August 2012 to May 
2013), in pediatric cancer patients aged between ≥1 to ≤17 years undergoing chemotherapy, applying a histori-
cally established standard TLDF of 39.0 °C ear temperature (NCT01683370).
It is important to note that this study comprised two study questions in different clinical situations. The first 
situation was diagnosis of FN: Both the analytical results on the influence of virtually applying different TLDFs on 
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FN diagnosis7 and the corresponding data descriptor10 have been published. The second situation was manage-
ment of patients after FN diagnosis. The analytical results on the influence of virtually applying different TLDFs 
on this management have been published as well11. The corresponding data on diagnostic measures, treatment 
escalation and hospital discharge after FN diagnosis is presented here.
Our aim to publish these data that they can be merged with other data, to study (1) the differences of clinical 
management when applying different TLDF; (2) to develop clinical decision algorithms based on higher TLDF 
with the ultimate goal to (3) derive better resource utilization and a more cost-efficient management. Such merg-
ing may be performed, for example, with the detailed clinical data available in the recently published Paediatric 
Intensive Care database12.
During a cumulative duration of 289 months of chemotherapy, 45 FN episodes were diagnosed in 20 patients 
(maximum, 6 episodes per patient)11. Of these, 12 (27%) episodes had been diagnosed by the treating physician 
at temperatures below 39.0 °C for clinical reasons7.
During these 45 FN episodes, a total of 3391 temperatures were measured (median per episode, 56; IQR, 40 
to 83; range, 7 to 401). Of these measurements, 193 were ≥39.0 °C (5.7%), and 937 ≥ 38.0 °C (27.6%) (Fig. 1). 
Furthermore, 318 (median per episode, 6; IQR, 5 to 7; range, 2 to 32) CBCs were performed. The ANC was 
≤0.5 G/L in 208 (65%) of them.
In total, 122 (median per episode, 2; range, 1 to 11) BC were taken. Of these, 10 (8.2%) were reported positive, 
but 1 (0.8%) was considered false positive11. Thus in 9 of the 45 FN episodes (20%), bacteremia was detected. 
Intravenous antibiotics were given for a median of 5.7 days (range, 1 to 43).
For persisting fever ≥48 hours, i.v.-antibiotics were escalated in 25 (56%) episodes. Moreover, for persisting 
fever ≥120 hours, i.v.-antifungals were added in 4 (9%) episodes. The median length of stay was 5.7 days (range, 
0.8 to 43.4).
These data can be used to simulate the effects of various TLDFs on the amount of diagnostic measures, on 
time-points and types of treatment escalation and on hospital discharge after FN diagnosis.
Regarding patients, there is an overlap of nearly 5 months (August 11, 2012, to December 31, 2012) with two 
separate data descriptors, both reporting retrospectively on patients under chemotherapy at risk to develop FN13, 
and on the corresponding FN episodes14 from January 1, 1993 to December 31, 2012. Except for temperatures 
that have led to FN diagnosis, there is no data overlap, however. Besides, the 45 temperature measurements and 
CBC leading to the diagnosis of FN in this study have been described before10.
Methods
These methods are detailed versions of the methods published in our corresponding analytical work11.
Study design. The data presented here have been collected during the prospective observational single 
center study “Pediatric FN Definition 2012 Bern” which was performed from August 2012 till May 2014 at the 
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, 
University of Bern, Switzerland9. The study was conducted in accordance with the Declaration of Helsinki. The 
study was approved by the Institutional Review Board (Ethikkommission der Universitätskinderkliniken Bern) 
and the trial had been registered at www.clinicaltrials.com (NCT01683370) before starting patient accrual. 
Written informed consent was obtained from the patients, if able to judge, and from their legal guardians prior 
to study entry. This study was supported by an unrestricted research grant from the Swiss Cancer League (Grant 
No. KLS-2933-02-2012).
The division of Pediatric Oncology and Hematology in Bern covers a population of around one million inhab-
itants. The Division of Pediatric Hematology/Oncology unit treats around 40 newly diagnosed pediatric patients 
per year and has an outpatient unit as well as an inpatient unit with eight beds. Furthermore autologous stem cell 
transplantations for the majority of Switzerland, covering around 6 million inhabitants, are performed here. A 
high TLDF (39.0 °C tympanic temperature) is used clinically. The data described here were not published together 
with the corresponding analytical results, because they had to be fully anonymized before data sharing in order to 
comply with the current Swiss research legislation7,11.



























Fig. 1 Temperature measurements in 45 FN episodes. Histogram depicting the 3391 temperatures measured 45 
FN episodes.
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Patients and routine clinical management. All patients aged 1 to 17 years diagnosed with cancer and 
who were treated at the Department of Pediatrics, Inselspital, Bern University Hospital, requiring chemotherapy 
for ≥2 months at time of recruitment, were eligible. Upon withdrawal of informed consent or completion of 
chemotherapy (≥2 weeks after last dose and absolute neutrophil count (ANC) > 0.5 G/L), patients were off study. 
Of 40 potentially eligible patients, 39 participated in this study. Further information on patients’ characteristics 
has been published elsewhere11.
Patients were treated with chemotherapy, according to internationally established protocols. Except for stand-
ard Pneumocystis jirovecii prophylaxis, no primary antimicrobial prophylaxis was used15,16. Diagnosis of FN was 
made when a patient with severe chemotherapy-induced neutropenia developed fever. Fever was defined as a 
single temperature of ≥39.0 °C measured in the ear. Severe neutropenia was defined as an ANC ≤ 0.5 G/L or 
≤1.0 G/L and expected to decline. If clinically indicated, the treating physician was free to diagnose FN at lower 
temperatures2,17,18.
Management of fever in neutropenia. Routine clinical measures after FN diagnosis included emergency 
hospitalization and taking blood cultures (BC) from the central venous access device. Further details on clinical 
management have been published2,18,19.
After the diagnosis of FN was made, usually with TLDF of 39.0 °C, empirical antimicrobial treatment was 
started, usually ceftriaxone plus amikacin. For persisting fever despite treatment, the following clinical rules were 
applied: Additional BC every 24 h; escalation of the empirical intravenous antibiotics, usually to meropenem plus 
vancomycin after 48 hours; and addition of empirical intravenous antifungals, usually liposomal amphotericin B, 
after 120 hours20. Patients were discharged when clinically well and afebrile for ≥48 hours, and when they had 
negative blood cultures plus signs of bone marrow recovery.
Data coverage of this study. This study collected data on temperature measurements, CBCs and diagnos-
tic and therapeutic measures during FN episodes. Data on temperature and CBCs performed outside of FN are 
published elsewhere10. Data collected at the intersections, i.e., at FN diagnosis and at the end of the FN episode, 
are published in both datasets.
Data Records
One single data record resulted from this trial, which contains a total of 45 single data files9, each for one specific 
FN episode. All the obtained data are published on Figshare: https://doi.org/10.6084/m9.figshare.5830236.v2.
Technical Validation
Reduction of recruitment bias. In order to reduce recruitment bias, all eligible patients from the cancer 
center were invited for study participation, regardless their diagnosis, age and gender. Only one patient denied 
study participation and so 39 of 40 eligible patients were recruited to participate. Thus, a relevant recruitment bias 
can be excluded. Furthermore, the participating study patients correspond to an unselected group of pediatric 
cancer patients regarding distribution of gender, age and diagnosis.
Data collection and increasing data reliability. Within the setting of a prospective clinical study, the 
data presented here was extracted by an experienced pediatric oncology nurse from the clinical chart records into 
a commercially available spreadsheet program. A pediatric oncologist (RAA) checked the data for plausibility 
and, if not plausible, for agreement with the chart records.
A simple restricted FN definition was applied, based on verifiable quantitative information on both fever and 
neutropenia. The treating physician was free to diagnose FN below the standard TLDF of 39.0 °C ear temperature 
if clinically indicated.
All temperature measurements were performed using a single type of thermometer (Braun ThermoScan 5; 
IRT 4520; Braun GmbH, Kronberg, Germany; steps displayed, 0.1 °C; accuracy, ±0.2 °C; clinical repeatability, 
±0.14 °C). CBC measurements were performed within clinical routine in a validated laboratory according to a 
standardized protocol.
Anonymization procedure. Before publication, data were irreversibly anonymized using three processes in 
order to comply with Swiss research legislation. First, a random four-digit number, not back trackable and inde-
pendent of the study patient identifier, was assigned to each patient. Second, data on diagnosis, age and gender, all 
considered to be potential identifiers, were deleted from the dataset. Third, the date of study start for each patient, 
as well considered a potential identifier, was replaced by day 0. Further days were correspondingly calculated 
from day 0 on. The real time of the day was expressed as a fraction of the day.
Code availability
No computer codes were used to generate the dataset. A commercially available spreadsheet program was used to 
collect the data and do quality checks.
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